期刊
FUTURE ONCOLOGY
卷 19, 期 2, 页码 103-111出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2022-0512
关键词
blast phase; decitabine; myeloproliferative neoplasms; secondary acute leukemia; venetoclax
类别
The evolution into a blast phase is a fatal event in myeloproliferative neoplasms, with a median survival of 3-6 months. Clinical trials with innovative approaches are needed for this category of patients. The ENABLE trial aims to test the combination of venetoclax and decitabine in patients with post-MPN blast phase, who have a poor prognosis.
Plain language summaryThe evolution into a blast phase represents a dramatic and often fatal event in the disease course of patients affected by myeloproliferative neoplasms. Aside from a minority of patients who can be offered an allogeneic transplant, the median survival from disease evolution is about 3-6 months. There is a serious unmet need for clinical trials with innovative approaches for this category of patients. In the ENABLE clinical trial, we aim to verify the efficacy and safety of the combination of venetoclax (a BCL2 inhibitor) and decitabine (a hypomethylating agent) in this disease subset, characterized by a complex dynamic of clonal evolution and a particularly unfavorable prognosis. The management of patients with acute myeloid leukemia (blast phase) secondary to myeloproliferative neoplasms (MPNs) is extremely challenging and the outcome dismal, with a median overall survival of about 3-6 months. Effective therapeutic approaches are lacking, especially when intensive strategies followed by allogeneic transplantation are not feasible. The combination of venetoclax and hypomethylating agents has recently been established as standard for newly diagnosed, unfit patients with de novo acute myeloid leukemia, but the application of this therapeutic modality has not been tested prospectively in the specific context of blast-phase MPNs. ENABLE is an open, phase II clinical trial aimed at verifying the efficacy and safety of the combination of venetoclax and decitabine in patients with post-MPN blast phase.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据